A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center to successfully detect lung cancer in a 2021 study has now detected more than 80% of ...

Doctors can diagnose fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), using blood tests that measure serum liver enzyme levels. Elevated enzyme levels ...

People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A Rutgers-led study in Science ...

Assessing the toxicity of food contaminants—including carcinogenic potential—is a major challenge in evaluating the risks ...

When you get the results from a routine blood screening, some familiar terms and numbers may jump out: cholesterol levels that point to a risk for heart disease, for example, and A1C, a blood sugar ...

Given just how much lifestyle disorders or non-communicable diseases are on the rise these days, it is quite likely that you would have taken a liver function test (LFT) and then consulted the doctor ...

According to the Centers for Disease Control and Prevention (CDC), approximately 25,000 men and 11,000 women are diagnosed with liver cancer each year. Early detection and treatment are key to ...

Shock liver is a sudden, acute type of liver disease that can cause liver failure. It happens when reduced blood flow to the liver causes liver cells to die. It is most common among people who have ...

Cancer diagnostics firm Helio Genomics says its five-year clinical trial shows its AI-based diagnostic test is two to four times more effective than typical ultrasounds. Helio’s pivotal trial, which ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic dysfunction-associated steatotic liver disease, or MASLD. The company said its 18 ...

Oncoguard® Liver blood test delivers six times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care. These findings will be presented as late-breaking data ...